Therefore, this study presents a novel delivery strategy for a functionally effective tau-targeting ASO, which could potentially enable systemic delivery of these promising therapeutics for Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.